ArticlePakistan journal of medical sciences2025
Clinical efficacy of losartan potassium combined with alprostadil in early diabetic nephropathy and its effect on renal function.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect of alprostadil combined with sulodexide on elderly chronic kidney disease patients and the independent risk factors affecting curative results.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To examine the effectiveness of the combination of losartan potassium and alprostadil in managing early diabetic nephropathy(DN) among patients and to determine its impact on renal function. Method: This was a retrospective comparative study. Eighty six patients with early DN treated in Heji Hospital Affiliated to Changzhi Medical College during March 2020 to March 2023 were selected and randomly assigned into two groups: the routine group(n=43) which received alprostadil therapy, and the intervention group(n=43) which received a combination of alprostadil and losartan potassium therapy, using an electronic grouping table. Compared the clinical efficacy, inflammatory indexes, renal function, and incidence of adverse drug reactions prior to and after treatment between the two groups. Results: The intervention group demonstrated a significantly higher clinical efficacy when compared to the routine group [97.67% vs. 86.05%, Conclusion: Losartan potassium combined with alprostadil in the treatment of early DN may improve renal function and inflammatory indexes in patients, with significant clinical efficacy but no increased adverse drug reactions. Moreover, it presents high safety of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.